A Phase 2, 2-panel, Open-label Randomized Study in Hepatitis C Virus Infected Subjects to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir and Ledipasvir in Treatment-naive Participants.
Phase of Trial: Phase II
Latest Information Update: 05 May 2017
At a glance
- Drugs Simeprevir (Primary) ; Ledipasvir/sofosbuvir; Sofosbuvir
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Janssen Sciences Ireland UC
- 17 Apr 2016 Results presented at The International Liver Congress™ 2016
- 17 Apr 2016 Status changed from recruiting to completed, as per the results presented at The International Liver Congress™ 2016.
- 11 Apr 2016 Data will be presented at The International Liver Congress 2016 of the European Association for the Study of the Liver (EASL), according to a Medivir AB media release.